SCHEMBL21035484

SCHEMBL21035484

FC(F)(F)C1(c2ccc(CCl)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 12/20 0.36
SIGMAR1 Q99720 1/20 0.36
EPHX2 P34913 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
OPRL1 P41146 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CACNA1G O43497 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C8 P10632 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2B6 P20813 1/20 0.31
CYP2C19 P33261 1/20 0.31
KCNH2 Q12809 1/20 0.31
CACNA1C Q13936 1/20 0.31
CACNA1I Q9P0X4 1/20 0.31
WDR5 P61964 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19302498 0.80 SIGMAR1 (0.39) CACNA1HSIGMAR1EPHX2NR1H4OPRL1
SCHEMBL24196140 0.80 LOXL2 (0.41) CACNA1HSIGMAR1
SCHEMBL21036238 0.80 PDK2 (0.37) CACNA1HSIGMAR1EPHX2NR1H4CACNA1G
SCHEMBL24196137 0.77 PDK2 (0.39) CACNA1HSIGMAR1OPRL1CA2
SCHEMBL25801644 0.76 CACNA1H (0.39) CACNA1HSIGMAR1CACNA1GCYP3A4CYP2C8
SCHEMBL25735734 0.76 PDK2 (0.40) CACNA1HSIGMAR1EPHX2NR1H4
SCHEMBL26014791 0.76 PTGS1 (0.40) SIGMAR1CYP2C9
SCHEMBL24851952 0.74 TRPA1 (0.30)
SCHEMBL24298656 0.73 GSK3B (0.47) CACNA1HSIGMAR1EPHX2NR1H4KDM4C
SCHEMBL24298716 0.73 PDE2A (0.36) CACNA1HSIGMAR1EPHX2NR1H4WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed